CA184-156: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) plus etoposide/platinum (EP) versus placebo plus EP in patients (Pts) with newly diagnosed extensive-stage disease small cell lung cancer (ED-SCLC).
Joachim Von Pawel
No relevant relationships to disclose
Sang-We Kim
No relevant relationships to disclose
David R. Spigel
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Christoph Zielinski
Honoraria - XXX
Maria Catherine Pietanza
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Honoraria - Bristol-Myers Squibb
Other Remuneration - Bristol-Myers Squibb
Veerle de Pril
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Marc S. Ballas
Employment or Leadership Position - Bristol-Myers Squibb
Consultant or Advisory Role - ImClone Systems; Lilly
Stock Ownership - Abbott Laboratories (I); Bristol-Myers Squibb; Novartis (I)
Honoraria - ImClone Systems; Lilly
Research Funding - AstraZeneca; ImClone Systems; Lilly; Pfizer
Other Remuneration - ImClone Systems; Lilly
Martin Reck
Consultant or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Pfizer; Roche
Honoraria - AstraZeneca; Daiichi Sankyo; Lilly; Roche